A federallyfunded study of a drug made by Intercept Pharmaceuticals Inc was stopped early in January in part because patients taking the drug experienced abnormal cholesterol levels according to emails between Intercepts chief medical officer and an official at the National Institutes of Health The emails obtained through a public records request indicate that Intercept was aware as early as Jan  that the cholesterol issue played a role in the NIHs decision to stop the study In its initial Jan  statement on the
  